Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer (Q37335448)

19 August 2017

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer (English)

1 reference

19 August 2017

phase I clinical trial

0 references

1 reference

1 reference

1 reference

10

Howard I Scher

1 reference

19 August 2017

4

Susan F Slovin

1 reference

19 August 2017

Michael J Morris

1

1 reference

19 August 2017

Daisy Huang

2

1 reference

19 August 2017

William K Kelly

3

1 reference

19 August 2017

Ryan D Stephenson

5

1 reference

19 August 2017

Caitlin Eicher

6

1 reference

19 August 2017

Anthony Delacruz

7

1 reference

19 August 2017

Tracy Curley

8

1 reference

19 August 2017

Lawrence H Schwartz

9

1 reference

19 August 2017

language of work or name

English

0 references

publication date

3 April 2009

1 reference

19 August 2017

1 reference

19 August 2017

56

1 reference

19 August 2017

2

1 reference

19 August 2017

237-244

1 reference

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738932

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

2 September 2018

1 reference

12 December 2020

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

1 reference

12 December 2020

Discussion of Dr. Huggins' paper: Control of cancers of man by endocrinological methods

1 reference

12 December 2020

Rapid androgen cycling as treatment for patients with prostate cancer.

1 reference

12 December 2020

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

1 reference

12 December 2020

10.1016/J.EURURO.2009.03.073

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19375217

1 reference